High-Throughput Peptide Array Clinical Validation for Lung Adenocarcinoma Detection.

Area of Science:

• Biochemistry
• Oncology
• Proteomics

Background:

• Protein dysregulation is central to complex diseases like lung cancer.
• Current protein array technology faces limitations in sensitivity, specificity, and cost for clinical use.
• Bloodstream peptides offer a promising alternative for diagnostic biomarker discovery.

Purpose of the Study:

• To develop a high-throughput peptide array for lung adenocarcinoma diagnosis and treatment monitoring.
• To create an array covering peptides from highly mutated and differentially expressed lung cancer proteins.
• To evaluate the array's utility in classifying diverse sample types for lung cancer surveillance.

Main Methods:

• Development of a high-throughput peptide array targeting peptides of 5-16 amino acids.
• Inclusion of peptides derived from high-mutation-frequency and differentially expressed proteins in lung adenocarcinoma.
• Concurrent detection and classification of five sample types: healthy controls, benign nodules, stage I lung adenocarcinoma, and pre- and postoperative samples.

Main Results:

• The peptide array successfully detected and classified five distinct sample types, including early-stage lung adenocarcinoma.
• Demonstrated potential for comprehensive lung cancer surveillance through peptide profiling.
• The array's design addresses limitations of traditional protein arrays for clinical proteomic analysis.

Conclusions:

• A novel peptide array platform shows significant potential for the early diagnosis and monitoring of lung adenocarcinoma.
• This technology offers a high-throughput, sensitive, and specific approach to proteomic analysis in clinical settings.
• Peptide array technology represents a promising advancement for lung cancer surveillance and personalized treatment strategies.